Results 21 to 30 of about 50,773 (265)

AIF1+CSF1R+ MSCs, induced by TNF‐α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis

Hepatology, EarlyView., 2022
Mesenchymal stem cells subset, educated by TNF‐α, are involved to generate inflammatory microenvironment and promote hepatocarcinogenesis Abstract Background and Aims Increasing evidence suggests that mesenchymal stem cells (MSCs) home to injured local tissues and the tumor microenvironment in the liver.
Chen Zong, Yan Meng, Fei Ye, Xue Yang, Rong Li, Jinghua Jiang, Qiudong Zhao, Lu Gao, Zhipeng Han, Lixin Wei   +9 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review [PDF]

Frontiers in Immunology, 2021
Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)/signal transducer and activator
Fei Qi, Fang Liu, Ling Gao
openaire   +3 more sources

Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor

Case Reports in Nephrology and Dialysis, 2021
Extramedullary hematopoiesis is widely known to occur in patients with primary myelofibrosis (PMF). Autopsy studies on individuals with PMF revealed that extramedullary hematopoiesis occurred in the kidneys in 35% of the cases, but there is little ...
Mea Asou, Tomohiko Asakawa, Makoto Araki, Takashi Ehara, Tsunekazu Hishima, Hisashi Sakamaki   +5 more
doaj   +1 more source

Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19

Brain Hemorrhages, 2021
Objectives: Intracerebral hemorrhage/bleeding (ICH) after an infection with SARS-CoV-2 (COVID-19) treated with the Janus-kinase inhibitor baricitinib has not been reported.
Josef Finsterer, Fulvio A. Scorza
doaj   +1 more source

Janus kinase inhibitors for the treatment of psoriatic arthritis

Indian Journal of Dermatology, Venereology and Leprology, 2023
Psoriatic arthritis (PsA), a systemic disease, has multi-domain musculoskeletal pathologies along with dermatological manifestations. The current recommendations and the standard of care for the treatment of PsA is to address the domain-based pathologies and the disease severity of the six clinical domains unique to PsA, namely, arthritis of the ...
Sanchita, Raychaudhuri, Ruchi, Jayeshbhai Shah, Smriti K, Raychaudhuri, Siba P, Raychaudhuri   +3 more
openaire   +2 more sources

A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib

BMC Infectious Diseases, 2019
Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk for various bacterial infections and viral reactivation.
Katya Prakash, Douglas Richman
doaj   +1 more source

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins. Currently, the preferred treatment for AIBD involves the use of glucocorticoids or traditional immunosuppressants.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
openaire   +3 more sources

Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan.

PLoS ONE
Anemia is associated with increased morbidity, mortality, healthcare resource utilization, and costs in myelofibrosis. This longitudinal, retrospective, and descriptive cohort study used a Japanese health administrative database (Medical Data Vision) to ...
Yusuke Yasutomi, Masashi Takano, Yi-Chen Chen, Chi-Chang Chen, Seok-Won Kim, Catherine McGuiness, Alex Slowley, Keita Kirito   +7 more
doaj   +1 more source

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

Clinical and Experimental Gastroenterology, 2023
Malcolm Irani,1 Christopher Fan,1 Kerri Glassner,1– 3 Bincy P Abraham1– 3 1Houston Methodist Gastroenterology Associates, Houston Methodist Hospital, Houston, TX, USA; 2Weill Cornell Medical College, New York, NY, USA; 3Houston Methodist Academic ...
Irani M, Fan C, Glassner K, Abraham BP
doaj